Revolution Medicines (Nasdaq: RVMD) will report its second quarter 2026 financial results on Wednesday, August 5, 2026, after market close. At 4:30 p.m. ET (1:30 p.m. PT), senior management will host a live webcast, with a replay available on the company’s investor relations website for at least 14 days.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
The two prior earnings-date notices were followed by positive 24-hour reactions of 2.54% and 2.96%, ...
Analysis
The two prior earnings-date notices were followed by positive 24-hour reactions of 2.54% and 2.96%, providing the closest platform comparison. The current notice remains a scheduling event; Net Selling is a separate risk factor.
Key Figures
Reporting period:Q2 2026Reporting date:August 5, 2026Webcast time:4:30 p.m. ET / 1:30 p.m. PT+1 more
4 metrics
Reporting periodQ2 2026Financial results scheduled for reporting
Reporting dateAugust 5, 2026After market close
Webcast time4:30 p.m. ET / 1:30 p.m. PTManagement webcast on August 5, 2026
Replay availabilityAt least 14 daysArchived webcast availability on the company website
"The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress"
A RAS (oncogene) is a family of genes that act like a cell’s growth switch; when they work normally they help cells respond to signals, but certain mutations can make the switch stuck in the ‘on’ position and drive uncontrolled cell growth. Investors watch RAS closely because mutations are common drivers of many cancers, and drugs that can safely target or correct RAS-driven growth can become major commercial opportunities or affect the value of companies developing such therapies.
g12c-selective inhibitormedical
"elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor"
A g12c-selective inhibitor is a drug designed to block the activity of a specific mutant form of the KRAS protein in which the amino acid at position 12 is changed to cysteine (G12C); it binds that altered spot and stops the mutant protein from sending growth signals in some cancers. Like putting a lock on a broken light switch, it targets a single malfunctioning driver of tumor growth. Its development and trial outcomes matter to investors because success or failure affects regulatory approval prospects, commercial market size for patients with the G12C mutation, and a company’s valuation, partnerships, and revenue forecasts.
g12d-selective inhibitormedical
"zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor"
A g12d-selective inhibitor is a drug designed to block the activity of a protein that carries the G12D mutation, a specific change in a cancer-driving gene (KRAS). It works by targeting only cells with that mutation, like a key made for a single lock, and matters to investors because trial results, regulatory decisions, and the size of the eligible patient group directly affect the drug’s commercial prospects and company value.
g12v-selective inhibitormedical
"RMC-5127, a RAS(ON) G12V-selective inhibitor"
A g12v-selective inhibitor is a drug designed to block the activity of a specific mutated form of the KRAS protein (the G12V mutation) that can drive cancer cell growth. Like a key cut to fit one lock, it aims to interfere only with cells carrying that mutation rather than normal cells, and it matters to investors because mutation-specific drugs can affect clinical trial design, approval paths, market size, and potential revenues tied to how common and treatable that mutation is.
REDWOOD CITY, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the second quarter of 2026 on Wednesday, August 5, 2026, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines’ senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.
To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcast, a replay will be available on the company’s website for at least 14 days.
About Revolution Medicines, Inc. Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.
Revolution Medicines Media & Investor Contact: media@revmed.com investors@revmed.com
FAQ
When will Revolution Medicines (RVMD) report its Q2 2026 financial results?
Revolution Medicines plans to report its Q2 2026 financial results on August 5, 2026, after market close. According to Revolution Medicines, this will be followed by a management webcast at 4:30 p.m. ET to discuss the quarter.
What time is the Revolution Medicines (RVMD) Q2 2026 earnings webcast on August 5, 2026?
The Revolution Medicines Q2 2026 webcast is scheduled for 4:30 p.m. ET (1:30 p.m. PT) on August 5, 2026. According to Revolution Medicines, senior management will discuss quarterly financial results and provide a corporate update during this event.
How can investors access the Revolution Medicines (RVMD) Q2 2026 earnings webcast and replay?
Investors can access the live and archived Q2 2026 webcast via the events and presentations section of Revolution Medicines’ investor relations website. According to Revolution Medicines, a replay will remain available on the site for at least 14 days.
Where can I find the Revolution Medicines (RVMD) investor relations events page for webcasts?
The Revolution Medicines investor events and presentations page is available through the company’s investor relations website at https://ir.revmed.com/events-and-presentations. According to Revolution Medicines, this page hosts live webcasts, archived replays, and related investor materials.
What type of company is Revolution Medicines (RVMD) and what does it develop?
Revolution Medicines is a late-stage clinical oncology company developing targeted therapies for RAS-addicted cancers. According to Revolution Medicines, its R&D pipeline centers on RAS(ON) inhibitors designed to address diverse oncogenic RAS variants across multiple specific mutations.
Which RAS(ON) inhibitor drug candidates are in Revolution Medicines (RVMD) clinical pipeline?
Revolution Medicines’ clinical RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib (RMC-6291), zoldonrasib (RMC-9805), and RMC-5127. According to Revolution Medicines, these candidates target multi-selective and specific RAS mutations such as G12C, G12D, and G12V.
Does Revolution Medicines (RVMD) have additional RAS(ON) mutant-selective programs beyond current clinical trials?
Yes, Revolution Medicines reports additional RAS(ON) mutant-selective programs including RMC-0708 (Q61H) and RMC-8839 (G13C). According to Revolution Medicines, these represent further development opportunities within its targeted oncology pipeline for RAS-addicted cancers.
